Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia substudy of an intima-media thickness trial

71Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

Abstract

Background - The lipid-lowering effects of statin therapy show considerable interindividual variation in patients with familial hypercholesterolemia (FH). Whether the type of LDL receptor mutation predicts the response to statin treatment is not yet established. We analyzed the relationship between LDL receptor genotype and response to pravastatin treatment in children with FH using carotid intima-media thickness (IMT) to measure efficacy. Methods and Results - In a randomized, placebo-controlled, double-blind, 2-year trial with pravastatin, 193 children had genetically confirmed FH and were included in the present substudy. At baseline, children with null alleles had higher LDL cholesterol levels (difference, 0.94±0.19 mmol/L [SEM]; P<0.001) and a greater carotid IMT (difference, 0.019±0.01 mm; P=0.02) compared with children with receptor-defective mutations. The decrease in carotid IMT during the trial was not significantly different in children with null alleles and receptor-defective mutations (0.018±0.012 and 0.012±0.010 mm; 2-way ANCOVA, P=0.7). After 2 years of treatment, the children with null alleles continued to have greater carotid IMT than children with receptor-defective mutations (difference, 0.016±0.01 mm; P=0.02). LDL cholesterol lowering tended to be less in carriers of null alleles compared with carriers of receptor-defective mutations (1.30±0.25 and 1.85±0.20 mmol/L; 2-way ANCOVA, P=0.08). Conclusions - In FH children, we found that the null allele genotype was associated with a greater carotid IMT, higher LDL cholesterol levels, and a nonsignificant tendency to attenuated LDL cholesterol lowering compared with receptor-defective mutations. Null alleles identify FH patients at the highest cardiovascular disease risk who may benefit from more aggressive treatment started in childhood. © 2005 American Heart Association, Inc.

References Powered by Scopus

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

27800Citations
N/AReaders
Get full text

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

7615Citations
N/AReaders
Get full text

A receptor-mediated pathway for cholesterol homeostasis

4669Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The Agenda for Familial Hypercholesterolemia: A Scientific Statement from the American Heart Association

575Citations
N/AReaders
Get full text

Noninvasive assessment of subclinical atherosclerosis in children and adolescents: Recommendations for standard assessment for clinical research: A scientific statement from the american heart association

555Citations
N/AReaders
Get full text

Mechanisms of disease: Genetic causes of familial hypercholesterolemia

496Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Koeijvoets, K. C. M. C., Rodenburg, J., Hutten, B. A., Wiegman, A., Kastelein, J. J. P., & Sijbrands, E. J. G. (2005). Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia substudy of an intima-media thickness trial. Circulation, 112(20), 3168–3173. https://doi.org/10.1161/CIRCULATIONAHA.105.565507

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 25

74%

Researcher 5

15%

Professor / Associate Prof. 4

12%

Readers' Discipline

Tooltip

Medicine and Dentistry 22

67%

Agricultural and Biological Sciences 5

15%

Biochemistry, Genetics and Molecular Bi... 4

12%

Nursing and Health Professions 2

6%

Save time finding and organizing research with Mendeley

Sign up for free